[Antileukotrienes in asthma - critical view].
This article discusses the role of cysteinyl leukotrienes in asthma and addresses the problem of the use of leukotriene receptor antagonists (LTRA) in the treatment of asthma. The author points out that these drugs are inferior to inhaled corticosteroids and long acting beta agonists and should be used as "add on" drugs being a third choice in the management of asthma. Lack of response to LTRA has a genetic background. Side effects of LTRA therapy is discussed, particularly Churg-Strauss syndrome. According to the recent literature, LTRA monotherapy should not be applied. In general, the author suggests that there is a risk of LTRA overtreatment particularly in children.
Droszcz
Wacław
W
D000085:Acetates / Q000009:adverse effects; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000517:prevention & control; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002648:Child; D015267:Churg-Strauss Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D004347:Drug Interactions; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D015289:Leukotrienes / Q000378:metabolism*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment
D000085:Acetates; D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D020024:Leukotriene Antagonists; D015289:Leukotrienes